Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus iodine-125 seed versus iodine-125 seed alone in advanced non-small-cell lung cancer after chemotherapy
ChiCTR1800018379Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: Progression-free survival. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800018379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018379.